263.07MMarket Cap-1921P/E (TTM)
3.470High3.300Low538.89KVolume3.400Open3.470Pre Close1.84MTurnover0.90%Turnover RatioLossP/E (Static)76.92MShares6.13052wk High1.76P/B204.77MFloat Cap2.00552wk Low--Dividend TTM59.87MShs Float28.300Historical High--Div YieldTTM4.90%Amplitude2.005Historical Low3.405Avg Price1Lot Size
Sutro Biopharma Stock Forum
Gear up for AACR24!
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
GlobeNewswire· 10 mins ago
Update
Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
loading...
loading...
Update/Blackrock!
SEC announcement· just
No comment yet